TT
The startup specializes in genetically engineering bacterial cells to produce difficult-to-express recombinant proteins for chronic disease treatment. Their proprietary technology enhances protein expression efficiency, enabling researchers to streamline protein production for therapeutic applications.
Updated 3 months ago
Funding
$900K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup specializes in genetically engineering bacterial cells to produce difficult-to-express recombinant proteins for chronic disease treatment. Their proprietary technology enhances protein expression efficiency, enabling researchers to streamline protein production for therapeutic applications.